These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26349393)

  • 1. Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles.
    Wang C; Shan Y; Yang J; Xu X; Zhuang B; Fan Y; Xu W
    J Biomed Nanotechnol; 2015 May; 11(5):805-15. PubMed ID: 26349393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization.
    Lai K; Li Y; Gong Y; Li L; Huang C; Xu F; Zhong X; Jin C
    Biomed Pharmacother; 2020 Nov; 131():110737. PubMed ID: 32932044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles.
    Xu L; Chen H; Xu H; Yang X
    Eur J Pharm Biopharm; 2008 Nov; 70(3):741-8. PubMed ID: 18761405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
    Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
    Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
    Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
    Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis.
    Zhang L; Chang J; Zhao Y; Xu H; Wang T; Li Q; Xing L; Huang J; Wang Y; Liang Q
    Int J Nanomedicine; 2018; 13():2051-2064. PubMed ID: 29670349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats.
    Zhang C; Peng F; Liu W; Wan J; Wan C; Xu H; Lam CW; Yang X
    Int J Nanomedicine; 2014; 9():1049-63. PubMed ID: 24591827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
    Wang C; Liu B; Xu X; Zhuang B; Li H; Yin J; Cong M; Xu W; Lu A
    Oncotarget; 2016 Feb; 7(7):8360-72. PubMed ID: 26840019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats.
    Xue M; Zhao Y; Li XJ; Jiang ZZ; Zhang L; Liu SH; Li XM; Zhang LY; Yang SY
    Eur J Pharm Sci; 2012 Nov; 47(4):713-7. PubMed ID: 22677813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas.
    Li X; Mao Y; Li K; Shi T; Yao H; Yao J; Wang S
    Drug Deliv; 2016 May; 23(4):1344-54. PubMed ID: 25853479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents.
    Xu L; Qiu Y; Xu H; Ao W; Lam W; Yang X
    Food Chem Toxicol; 2013 Jul; 57():371-9. PubMed ID: 23583804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity.
    Zheng W; Wang C; Ding R; Huang Y; Li Y; Lu Y
    Int J Pharm; 2019 Dec; 572():118721. PubMed ID: 31626922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of Triptolide-loaded pluronic P105 polymeric micelles.
    Li H; Wen XS; Di W
    Arzneimittelforschung; 2012 Jul; 62(7):340-4. PubMed ID: 22588630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney-targeted triptolide-encapsulated mesoscale nanoparticles for high-efficiency treatment of kidney injury.
    Deng X; Zeng T; Li J; Huang C; Yu M; Wang X; Tan L; Zhang M; Li A; Hu J
    Biomater Sci; 2019 Dec; 7(12):5312-5323. PubMed ID: 31617509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo.
    Zhang L; Wang T; Li Q; Huang J; Xu H; Li J; Wang Y; Liang Q
    Int J Nanomedicine; 2016; 11():2663-73. PubMed ID: 27354796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
    Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
    Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of Triptolide and Triptolide loaded polymeric micelles in vitro.
    Zheng S; Löw K; Wagner S; Yang X; von Briesen H; Zou S
    Toxicol In Vitro; 2011 Dec; 25(8):1557-67. PubMed ID: 21640813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
    Yang M; Gu Y; Yang D; Tang X; Liu J
    J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
    Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
    ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4.
    Zheng N; Wei A; Wu T; Long L; Yang H; Li H; Wang L
    Toxicol Lett; 2021 May; 342():85-94. PubMed ID: 33600922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.